F-1/A: Polyrizon Ltd. Files for IPO, Offering Units with Warrants

Polyrizon Ltd. is seeking to go public, offering units consisting of ordinary shares and warrants, as well as pre-funded units for certain investors.

Summary

• Polyrizon Ltd., a development stage biotech company, has filed a registration statement for an initial public offering (IPO).
• The company plans to offer 807,692 units, each comprising one ordinary share and three warrants to purchase ordinary shares.
• The anticipated IPO price per unit is between $4.38 and $6.02, with an assumed warrant exercise price of $5.20.
• Polyrizon is also offering up to 807,692 pre-funded units to investors who would otherwise exceed beneficial ownership limits, with each pre-funded unit containing a pre-funded warrant and three warrants.
• The purchase price of each Pre-Funded Unit will equal the price per Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant included in the Pre-Funded Unit will be $0.001 per Ordinary Share.
• The company has applied to list its ordinary shares on the Nasdaq Capital Market under the symbol PLRZ.
• Certain existing shareholders have indicated an interest in purchasing up to $1 million of Ordinary Shares in this offering at the initial public offering price per share.
• The company has granted the underwriter an option to purchase additional Ordinary Shares and/or Warrants and/or Pre-Funded Warrants within 45 days from the date of this prospectus to cover over-allotments, if any.
• The company intends to use the net proceeds from this offering for preclinical and clinical development of its product candidates, repayment of convertible loan agreements, and for working capital and general corporate purposes and possible future acquisitions.
• The company has registered an aggregate of 3,116,851 Ordinary Shares for resale by certain shareholders, or the Selling Shareholders, by means of a separate prospectus.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company and the risks associated with investing in it. The company's financial situation and dependence on future funding are significant concerns, but the potential market opportunities and experienced management team are positive factors.

Positives

• The company has a clear plan for the use of proceeds from the IPO.
• The company has attracted interest from existing shareholders to purchase up to $1 million in the offering.
• The company has a strong management team with experience in the life sciences industry.
• The company has a Scientific Advisory Board which is an advisory panel of professors with expertise in drug delivery systems, chemistry and pharmaceuticals.

Negatives

• The company has incurred significant losses since its inception and anticipates continuing to incur losses.
• The company has never generated any revenue from product candidates sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company is heavily dependent on the success of its C&C product candidates.
• The company is an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our Ordinary Shares less attractive to investors.
• The company is heavily dependent on the success of its C&C product candidates.

Risks

• The company may not receive, or may be delayed in receiving, the necessary clearances or approvals for its product candidates.
• The company faces intense competition in an environment of rapid technological change.
• The company will rely on third parties to conduct certain elements of its preclinical studies and clinical trials.
• The company may be subject to claims that its employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.
• The market price of the company's securities may be highly volatile, and you may not be able to resell your Ordinary Shares at or above the initial public offering price.
• The company may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws.

Future Outlook

The company expects its expenses and operating losses to increase for the foreseeable future as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The company operates in the competitive medical device and pharmaceutical industry, where new technologies and products are constantly being developed. The company's success will depend on its ability to compete effectively and to adapt to changes in the industry.

Comparison to Industry Standards

• The FDA submission and clearance process for Alzair, Nasalese, and Bentrio, comparible products to the PL-14 product candidate, took 86 and 140 days, respectively.
• The global cold and cough remedies market is valued at $42.65 billion in 2024 and is expected to grow at a CAGR of 6.18% from 2024 to 2029.
• The global therapeutic market for allergic rhinitis is projected to reach $16 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032.
• The global allergen blocker market will reach $214.5 million in 2030, growing at a CAGR of 3.64% during 2023-2030.
• The global market for intranasal drug delivery is projected to reach $136.46 billion by 2032, growing at a CAGR of 7.18%.
• The INCS products market is estimated to reach $11.2 billion by 2033.
• The benzodiazepine drugs market is expected to reach $4.2 billion by 2032, which reflects a CAGR of 3.7% during 2024-2032.
• The market for Benzodiazepines for seizure clusters is estimated to be around $700 million.
• The global naloxone market is expected to grow to $2.47 billion in 2032, at a CAGR of 11% between 2023 and 2032.
• The naloxone intranasal spray market is projected to attain a value of $1.4 billion by 2030.
• The global pain management drugs market size was estimated at $78.14 billion in 2022 and is projected to hit around $115 billion by 2032, growing at a CAGR of 3.94% during the forecast period 2023 to 2032.

Related Party Transactions

• XYLO Purchase Agreement: We entered into a share purchase agreement, or the XYLO Purchase Agreement, with Medigus Ltd. (which subsequently changed its name to Xylo Technologies Ltd.), or XYLO, pursuant to which we issued a total of 43,964 of our Ordinary Shares, at a price per share of $2.36 for aggregate gross proceeds of $104,000.
• August 2021 Share Purchase Agreement: On August 25, 2021, we entered into a Share Purchase Agreement with certain investors, including Tomer Izraeli, our Chief Executive Officer, XYLO, Sara Srugo and Reuven Srugo Construction Company Ltd., a Company owned by Raul Srugo, pursuant to which we issued 688,060 Ordinary Shares, at a price per share of $1.13 for aggregate net proceeds of $779,971.
• June 2023, December 2023 and May 2024 Share Purchase Agreements: In June 2023, December 2023 and May 2024, we entered into a series of securities purchase agreements with certain of our principal shareholders, including XYLO, Raul Srugo, Itzhak Srugo, Yoav Srugo and Sofi Yochelman Srugo, pursuant to which we issued an aggregate of 513,878 Ordinary Shares for gross proceeds of $582,000.
• Convertible Loan with XYLO: On February 4, 2023, we entered into a convertible loan agreement with Medigus Ltd. (which subsequently changed its name to Xylo Technologies Ltd.), pursuant to which XYLO extended a loan to the Company in the principal amount of $80,000, with an annual interest rate of approximately 4%.
• Convertible Loan with Reuven Srugo Construction Company Ltd.: On February 4, 2023, we entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., or Reuven Construction, pursuant to which Reuven Construction extended a loan the Company in the principal amount of $100,000, with an annual interest rate of approximately 4%.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of new shares and the volatility of the market price.
• Employees may be impacted by the company's ability to attract and retain qualified personnel.
• Customers may benefit from the development of new and innovative product candidates.
• Suppliers may benefit from the company's increased demand for raw materials and manufacturing services.

Next Steps

• Complete preclinical development for PL-14, PL-15 and PL-16 product candidates.
• Complete clinical development for PL-14 product candidate.
• Complete in vitro feasibility studies of corticosteroid, benzodiazepine, naloxone for T&T platform technology product candidates.
• Repay the April 2024 CLA and August 2024 CLA.
• Initiate preclinical safety trials for PL-14, PL-15 and PL-16 product candidates in the second quarter of 2025.
• Commence pivotal clinical trial on PL-14 product candidate in the fourth quarter of 2025.
• Initiate feasibility clinical trial for PL-16 product candidate in the first quarter of 2026.
• Begin pre-clinical studies for T&T platform product candidates in the second quarter of 2026.
• Initiate feasibility clinical trial for PL-15 product candidate in the third quarter of 2026.
• Commence pivotal clinical trials for PL-16 product candidate in the third quarter of 2026.
• Commence pivotal clinical trials for PL-15 product candidate in the second quarter of 2027.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2027.

Key Dates

Keywords

IPO, Polyrizon, Ordinary Shares, Warrants, Pre-Funded Units, Medical Device, Hydrogels, Nasal Sprays, Biotech, PLRZ